Prostate Cancer

A discussion surrounding the changing landscape of early-stage prostate cancer screening and rise in metastatic disease cases, focusing on the importance of timely intervention and patient-focused care.

Insight into advancements in prostate cancer imaging using PSMA agents like gallium and F-18, their unique characteristics, and the considerations in choosing the right radiotracer for accurate detection.

The phase 3 EMBARK trial showed that enzalutamide plus leuprolide reduced the risk of metastasis or death by nearly 60% vs leuprolide alone in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

Delve into the strategic process of selecting ideal partners in cancer care as key opinion leaders share insights on building trust, effective communication, and optimizing patient outcomes through collaborative decision making.

Explore how David Morris, MD, FACS, and Benjamin Garmezy, MD, join forces to enhance patient outcomes in advanced prostate cancer through their innovative and collaborative precision medicine strategies.

“Where we are with this, I think that our results do not support the theory that agonists have a higher cardiovascular risk than antagonists,” says E. David Crawford, MD.

Amir H. Lebastchi, MD, provides perspectives on the VIOLETTE study and underscores the importance of future head-to-head trials to gain a deeper understanding of various treatment approaches.

"Hopefully this law will allow more patients with advanced prostate cancer to gain access to these medications, and to take it without substantially changing the quality of their life when it comes to financial consequences," says Benjamin Pockros, MD.

"Hopefully this gives patients and providers information that they can use to inform and set reasonable expectations of what patient's lives will look like after treatment," says Samuel L. Washington III, MD, MAS.

Explore the transformative journey of prostate cancer imaging techniques, from conventional methods to cutting-edge PET scans like F-18 PSMA, and how FDA approvals have shaped their adoption.

Join David Albala, MD, as he explores the use of advanced imaging techniques in prostate cancer diagnosis and management, highlighting PSMA-PET scans and their pivotal role in modern prostate cancer care.

“The ClarityDX Prostate test will reduce the number of unnecessary prostate biopsies, which are invasive, uncomfortable, and carry some risk,” says John D. Lewis, PhD.

"It's really a monumental change for patients, and it is a massive win for our health care system," says Benjamin Pockros, MD.

Dr. Amir H. Lebastchi elaborates on his approach to integrating MRI and ultrasound fusion-based technology for guiding treatment selection and tailoring therapy for patients with prostate cancer.

Amir H. Lebastchi, MD, outlines his general strategy for active surveillance in prostate cancer patients, emphasizing the role of MRI and fusion-guided prostate biopsy.

Preliminary findings from the study showed a decrease in PSA levels across all doses of PDS0301 assessed.

The phase 2 study explored the investigational agent BXCL701 in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer.

“I think this study gives us actual numbers, so we can have a sense of how much time people will take off over time,” says Samuel L. Washington, MD, MAS.

"A lot of patients with prostate cancer are going to receive one of these agents," says Tanya B. Dorff, MD.

"It's not just teaching all about prostate cancer; it's real life and how people are experiencing prostate cancer," says David F. Mobley, MD.

Dr. Amir H. Lebastchi reviews retrospective data comparing software-based and cognitive-based fusion biopsy approaches, providing valuable insights into the findings.

Amir H. Lebastchi, MD, explores the evolving landscape in the context of fusion-guided prostate biopsy methods.

In the second article of the series, Paul Sieber, MD, shares best practices for the administration of leuprolide in patients with advanced/metastatic prostate cancer.

“There are always other aspects of care other than that immediate treatment period that's needed,” says Samuel L. Washington III, MD.

Patients who underwent treatment with SBRT demonstrated a 5-year disease control rate of 96%, compared with 95% among patients who underwent conventionally fractionated radiation therapy.

In the first article of this series, Benjamin H. Lowentritt, MD, FACS, gives an overview of micronized abiraterone and its role in the treatment of patients with metastatic castrate-resistant prostate cancer.

In the second interview of the series, Paul Sieber, MD, provides expert insights on the management of adverse effects seen in patients receiving leuprolide for the treatment of advanced/metastatic prostate cancer.

Dr Amir H. Lebastchi delves into the latest advancements and evolving tactics in the field of prostate cancer biopsy and diagnostic procedures.